本帖最后由 老马 于 2012-1-13 21:20 编辑
( {) S' G# f+ Y, I. D- W0 A U6 G3 I* }1 s" v! y+ p
爱必妥和阿瓦斯丁的比较% N- x9 } C' G. L( P
. z% M6 Y4 K( S
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 p( k# D! N$ ?5 ^. @8 ~+ G
, T: X# W3 F0 v8 P: g
- H) Z7 `: O, i' q# C: \http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ t) T P) a. I. I: x
==================================================
: n9 b/ l0 L+ R+ L, ^( y) l8 d& ^8 NOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)7 k) n- K$ s# u- ^9 N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point." O" J* n( p7 q- Z. t s5 e
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' b$ K0 J! B, ^" P/ [1 n5 j
|
电场治疗癌症业余实现的探讨
2023.10.23 初版
2023.10.25 加一个PDF附件，删除个别错字
2023.10.27 增加功率放
K 满2年之后怎么办，免疫满两年的思
今天东肿义诊，人山人海，我去排了大专家的号，想问问免疫满两年之后我们要怎么办。从
求助！双下肢发麻无力，大小便失禁，
年龄：50
性别：男
一、基本情况：
2022年2月4日：确诊肺腺癌，分期：T2N3M1（IVB期)
作为肿瘤患者，胃药可不能乱吃！
经常有患者提问说，吃靶向药期间胃痛、胃胀、烧心、反酸等情况，应该如何处理。
原则
忆五年~我和父亲的抗癌历程，爸爸走
2017年的9月6日，我的父亲在天津市第四中心医院，因为长期的后背疼痛经过医院
显身卡
, b8 c3 r* A5 ]! T' q
